The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial - Takeaways - MDSpire

The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial

  • By

  • Aiden V Brossfield

  • Donald J McMahon

  • Jason Fernando

  • Beatriz Omeragic

  • Rukshana Majeed

  • Sanchita Agarwal

  • Grazyna E Sroga

  • Bowen Wang

  • Deepak Vashishth

  • Mishaela R Rubin

  • October 8, 2024

  • 0 min

Share

  • 1

    Pyridoxamine (PM) treatment increased the bone formation marker P1NP by 23.0% in older women with type 2 diabetes compared to 4.1% in the placebo group.

  • 2

    Bone mineral density (BMD) at the femoral neck improved significantly with PM, showing a 2.6% increase versus a 0.9% decrease in the placebo group.

  • 3

    PM treatment led to a significant decrease in HbA1c levels, with a reduction of 0.38% compared to a 0.05% increase in the placebo group.

  • 4

    The study found a strong correlation between changes in HbA1c and P1NP levels within the PM group, indicating a potential link between glycemic control and bone health.

  • 5

    Pyridoxamine may represent a novel therapeutic approach to improve bone health and reduce fracture risk in older women with type 2 diabetes.

Original Source(s)

The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial

  • by Aiden V Brossfield, Donald J McMahon, Jason Fernando, Beatriz Omeragic, Rukshana Majeed, Sanchita Agarwal, Grazyna E Sroga, Bowen Wang, Deepak Vashishth, Mishaela R Rubin

  • October 8, 2024

Related Content

Phosphaturic mesenchymal tumor in the temporalis muscle causing tumor-induced osteomalacia: a case report and literature review

Utilizing Machine Learning to Identify Risk Factors for Diabetic Microvascular Complications and Develop a Predictive Model with Gradient Boosting Decision Trees

A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues